Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life

Journal of Infectious Diseases

Volumn 196, Issue 9, 2007, Pages 1339-1345

  Nair, Nitya ^a   Gans, Hayley ^b   Lew Yasukawa, Linda ^b,c   Long Wagar, Andrea C ^a   Arvin, Ann ^b   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MMR II; UNCLASSIFIED DRUG; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES; MUMPS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; RUBELLA; SINGLE DRUG DOSE; AGING; ANTIBODY AFFINITY; BLOOD; CLASSIFICATION; CLINICAL TRIAL; FEMALE; IMMUNIZATION; IMMUNOLOGY; MALE; PASSIVE IMMUNIZATION;

AGING; ANTIBODY AFFINITY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INFANT; MALE; MEASLES; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 38449118179     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522519     Document Type: Article

References (36)

1. Progress in reducing global measles deaths: 1999-2004. Wkly Epidemiol Rec 2006; 81:90-4.
2. Cutts FT, Henao-Restrepo A, Olive JM. Measles elimination: progress and challenges. Vaccine 1999; 17(Suppl 3):S47-52.
3. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21:3406-12.
4. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003; 21:3398-405.
5. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447-50.
6. Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996; 97:53-8.
7. Aaby P, Ibrahim SA, Libman MD, Jensen H. The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine 2006; 24:2764-71.
8. Cutts FT, Nyandu B, Markowitz LE, et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 1994; 12:1311-6.
9. Knudsen KM, Aaby P, Whittle H, et al. Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 1996; 25:665-73.
10. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003; 361:2183-8.
11. Kumar ML, Johnson CE, Chui LW, Whitwell JK, Staehle B, Nalin D. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine 1998; 16:2047-51.
12. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26.
13. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
14. Gans HA, Yasukawa LL, Alderson A, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004; 190:83-90.
15. Bouche FB, Ertl OT, Muller CP. Neutralizing B cell response in measles. Viral Immunol 2002; 15:451-71.
16. Olszewska W, Obeid OE, Steward MW. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity. Virology 2000; 272:98-105.
17. Rahman J, Loh J, Staines NA. Low-affinity antibodies against collagen type II produced by lymph node cells are associated with pathology in collagen-induced arthritis in rats. Clin Exp Immunol 1992; 88:461-6.
18. Devey ME, Bleasdale K, Stanley C, Steward MW. Failure of affinity maturation leads to increased susceptibility to immune complex glomerulonephritis. Immunology 1984; 52:377-83.
19. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003; 9:1209-13.
20. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, Steward MW. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995; 99:175-81.
21. de Souza VA, Pannuti CS, Sumita LM, de Andrade Júnior HF. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol 1997; 52:275-9.
22. Pannuti CS, Morello RJ, Moraes JC, et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diagn Lab Immunol 2004; 11:119-22.
23. Macdonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988; 106:191-4.
24. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999; 162:5569-75.
25. Gans HA, Yasukawa LL, Alderson A, et al. T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunol 2004; 17:298-307.
26. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 2001; 30:241-7.
27. Schroeder HW Jr, Mortari F, Shiokawa S, Kirkham PM, Elgavish RA, Bertrand FE 3rd. Developmental regulation of the human antibody repertoire. Ann NY Acad Sci 1995; 764:242-60.
28. Ridings J, Dinan L,Williams R, Roberton D, Zola H. Somatic mutation of immunoglobulin V(H)6 genes in human infants. Clin Exp Immunol 1998; 114:33-9.
29. Lucas AH, Azmi FH, Mink CM, Granoff DM. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide. J Immunol 1993; 150:2056-61.
30. Plebani A, Ugazio AG, Avanzini MA, et al. Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile charts. Eur J Pediatr 1989; 149:164-7.
31. Servet-Delprat C, Bridon JM, Djossou O, Yahia SA, Banchereau J, Briere F. Delayed IgG2 humoral response in infants is not due to intrinsic T or B cell defects. Int Immunol 1996; 8:1495-502.
32. Isa MB, Martinez L, Giordano M, Passeggi C, de Wolff MC, Nates S. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin Diagn Lab Immunol 2002; 9:693-7.
33. Isa MB, Martinez L, Giordano M, et al. Measles virus-specific immunoglobulin G isotype immune response in early and late infections. J Clin Microbiol 2001; 39:170-4.
34. El Mubarak HS, Ibrahim SA, Vos HW, et al. Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection. J Med Virol 2004; 72:290-8.
35. Toptygina AP, Pukhal'skii AL, Mamaeva TA, Aleshkin VA. Spectrum of anti-measles immunoglobulin G subclasses in convalescents after measles. Bull Exp Biol Med 2004; 137:259-61.
36. Toptygina AP, Pukhalsky AL, Alioshkin VA. Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history. Clin Diagn Lab Immunol 2005; 12:845-7.